New Study Quantifies the Cost of Dropping Federal MMRV Recommendations for Toddlers

What the Advisory Committee Did — and Didn't Do

In September 2025, the Advisory Committee on Immunization Practices (ACIP) voted to remove its federal recommendation for MMRV, the combination vaccine covering measles, mumps, rubella, and varicella (chickenpox). ACIP advises the Centers for Disease Control and Prevention and its recommendations determine whether insurers must cover a vaccine and whether it qualifies for the federal Vaccines for Children program.

The vote came without a standard ACIP decision-making framework that the committee has historically used to evaluate real-world impacts on children. According to Ars Technica's reporting on the JAMA Network Open study, the panel did not even address basic questions such as which children would be directly affected. ACIP's current membership was assembled by Health and Human Services Secretary Robert F. Kennedy Jr.

The practical result: private insurers are no longer required to cover MMRV, and the shot is no longer available through the Vaccines for Children program, which provides vaccines to roughly half of American children — predominantly from low-income households.

What the Researchers Found

Researchers in Washington state went back and did the analysis ACIP skipped. Published in JAMA Network Open, the study examined immunization records for more than 200,000 children ages 12 to 47 months in King County — which includes Seattle — covering 2015 through 2025. They found that just over 31,000 of those children received MMRV, roughly 15 percent.

That 15 percent figure tracks with national usage data. The majority of children receive the MMR vaccine and a separate varicella shot administered at the same appointment, a combination abbreviated MMR+V.

Why Most Kids Already Got MMR+V Instead

The preference for the separate shots has a documented medical basis. MMRV received FDA approval in 2005, but post-approval surveillance identified a slightly elevated risk of febrile seizures when given as a first dose to toddlers aged 12 to 15 months. The numbers: 7 to 8.5 febrile seizure cases per 10,000 first-dose MMRV vaccinations, compared to 3.2 to 4.2 per 10,000 first-dose MMR+V vaccinations. That translates to roughly one additional febrile seizure for every 2,300 to 2,600 children.

Febrile seizures are seizures triggered by fever. They are generally not harmful and can be caused by nearly any fever-inducing illness. The increased risk applied only to the first dose; no elevated risk was observed with the second dose, given at ages 4 to 6.

So the pre-existing clinical guidance already steered most providers and parents toward MMR+V on safety grounds. The 15 percent who were getting MMRV were doing so for reasons like needle aversion or logistical preference — one shot instead of two.

The Fairest Case for the ACIP Decision

The strongest argument on the other side is this. If only 15 percent of children were using MMRV, and the existing preference for MMR+V was already evidence-based, then removing the federal MMRV recommendation could be framed as trimming a redundant option with a documented, if small, safety signal. A reasonable reading says the committee removed a combination shot that most clinicians already avoided for the first dose, in favor of a two-shot protocol that had become the de facto standard anyway. Under that logic, no children lose access to measles, mumps, rubella, or varicella protection. They just get the shots separately.

The JAMA Network Open study directly challenges that framing, however. The researchers focused on who was actually using MMRV. Children who received MMRV were more than three times more likely than other vaccinated children to be eligible for the federal program that offers free vaccines to low-income families, and nearly four times more likely to be vaccinated at a safety-net clinic. Given that the Vaccines for Children program serves low-income families who may face higher logistical barriers, removing one of those two shots from the federal formulary could mean the varicella dose simply does not get administered. A two-shot protocol only works if both shots are given.

The ACIP panel's September vote did not model that scenario. It did not estimate how many children in the Vaccines for Children program would see reduced varicella coverage as a downstream result. It did not produce a risk-benefit framework comparing the marginal febrile seizure risk of MMRV against the risk of missed varicella vaccination in a specific population. The JAMA Network Open researchers were filling that gap.

Health policy experts Elizabeth Cope and Aaron Carroll of AcademyHealth, writing in an accompanying commentary, put it plainly: "Combination vaccines reduce the number of injections and visits and lower cost barriers to series completion. Those benefits matter most to families with the least slack: hourly work, no paid sick leave, and a follow-up visit that may not happen."

The Open Question

The federal Vaccines for Children program no longer covers MMRV. What remains unknown is whether the CDC, HHS, or Congress will request a formal reassessment using the standard ACIP analytical framework. Cope and Carroll note the study's limitation — it examines only one county in one state — but warn that "if similar patterns exist in less well-resourced settings, the resulting equity implications could be even more pronounced."